Kodiak Sciences (NASDAQ:KOD) Stock Price Expected to Rise, HC Wainwright Analyst Says

Kodiak Sciences (NASDAQ:KOD) had its price target upped by stock analysts at HC Wainwright from $96.00 to $126.00 in a research report issued on Monday, Marketbeat.com reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 37.51% from the company’s current price. HC Wainwright also issued estimates for Kodiak Sciences’ FY2030 earnings at $6.24 EPS.

A number of other equities research analysts have also recently weighed in on KOD. UBS Group lifted their price objective on shares of Kodiak Sciences from $80.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, September 28th. Lifesci Capital increased their target price on shares of Kodiak Sciences from $85.00 to $145.00 and gave the company an “outperform” rating in a research report on Monday, September 28th. JPMorgan Chase & Co. increased their target price on shares of Kodiak Sciences from $56.00 to $66.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Weiss Ratings cut shares of Kodiak Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, October 6th. Finally, Wall Street Zen upgraded shares of Kodiak Sciences from a “strong sell” rating to a “sell” rating in a research report on Sunday, October 4th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.71.

Kodiak Sciences Price Performance

Shares of Kodiak Sciences stock opened at $91.63 on Monday. The business’s fifty day moving average price is $50.99 and its two-hundred day moving average price is $43.35. The company has a market capitalization of $5.76 billion, a P/E ratio of -21.87 and a beta of 2.03. Kodiak Sciences has a 1-year low of $10.94 and a 1-year high of $104.00.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.09). On average, research analysts expect that Kodiak Sciences will post -3.97 earnings per share for the current fiscal year.

Insider Transactions at Kodiak Sciences

In other news, Director Bros. Advisors Lp Baker purchased 807,840 shares of the stock in a transaction dated Monday, September 28th. The shares were bought at an average cost of $72.57 per share, for a total transaction of $58,624,948.80. Following the transaction, the director owned 19,121,134 shares in the company, valued at $1,387,620,694.38. This trade represents a 4.41% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders acquired 1,941,755 shares of company stock worth $156,986,026. Company insiders own 44.40% of the company’s stock.

Institutional Trading of Kodiak Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Arizona State Retirement System increased its position in shares of Kodiak Sciences by 6.9% in the second quarter. Arizona State Retirement System now owns 8,533 shares of the company’s stock worth $332,000 after acquiring an additional 554 shares in the last quarter. V Square Quantitative Management LLC acquired a new stake in shares of Kodiak Sciences during the first quarter valued at approximately $26,000. Westfuller Advisors LLC purchased a new stake in shares of Kodiak Sciences in the 1st quarter valued at approximately $26,000. EverSource Wealth Advisors LLC lifted its position in shares of Kodiak Sciences by 94.5% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,927 shares of the company’s stock valued at $73,000 after acquiring an additional 936 shares in the last quarter. Finally, KBC Group NV purchased a new stake in shares of Kodiak Sciences in the 1st quarter valued at approximately $39,000. Institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Company Profile

Kodiak Sciences Inc (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing medicines for serious retinal diseases. The company’s research is centered on its Antibody Biopolymer Conjugate (ABC) platform, which is designed to combine antibody-based therapies with biopolymer technology to potentially extend the duration of treatment in the eye.

Kodiak’s lead programs have focused on ophthalmic diseases involving abnormal blood-vessel growth or leakage, including wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion.